Early detection of multiple diseases from a single blood test
Adaptive has partnered with Microsoft Healthcare NExT initiative to map and decode the human immune system, nature’s most finely tuned diagnostic. Together we are using immunosequencing, proprietary computational modeling, and machine learning to map T-cell receptor (TCR) sequences to the antigens they bind. Using this data, we aim to translate the natural diagnostic capability of the immune system into the clinic.
We are building a map that links trillions of TCRs with the millions of clinically-relevant antigens they are specifically targeted to attack, making the diagnosis of disease far more efficient and precise. This will make it possible to read what an immune system has fought or is currently fighting, with the goal of creating a better diagnostic for all diseases—from cancer to autoimmune conditions to infectious diseases.
As part of this collaboration, we are interested in investigating sample sets that can be mined for disease-associated TCRs, on the scale of 100s to 1000s of samples, in the disease areas mentioned below.
Learning to decode the immune system to diagnose disease
The immune system is nature’s most finely-tuned diagnostic, providing a fingerprint of a person’s health in their blood
We read immune signatures that store the diagnostic information
We generate a map of the immune system by matching trillions of T cells to the diseases they recognize
This map of the immune system may be used by doctors and researchers to improve disease diagnosis
This landmark collaboration is a cornerstone of the Microsoft Healthcare NExT initiative, and the first and only biotech and tech effort focused on revealing and translating insights about the immune system into actionable tools for clinicians.
The core of the TCR-Antigen Map is the biological data and models derived from Adaptive’s high-throughput, patented sequencing and antigen-mapping technologies (immunoSEQ and MIRA, respectively) to determine all possible T-cell receptors that bind to clinically relevant antigens across diseases. A proof-of-concept for this initiative was published in Nature Genetics (Emerson, et al. Nat Genet. 2017), demonstrating our ability to identify TCRs capable of diagnosing cytomegalovirus (CMV). Now we are working to expand this effort to develop diagnostic tests in other diseases, with the vision of ultimately developing a diagnostic for multiple diseases from a single blood test based on the breadth of knowledge within the adaptive immune system.
After two years in partnership, Adaptive and Microsoft have made enormous strides in building the infrastructure to solve this biological puzzle. To accelerate our progress, we have integrated the distinct capabilities of each our teams to an unprecedented degree. In 2019, we achieved a key milestone of establishing a proof of concept in acute Lyme disease. Looking ahead to our next milestones, we plan to confirm the first indications to bring to the FDA for review while continuing signal validation in several additional indications. We are currently seeking samples to validate our technology in several areas of focus, including but not limited to:
Other diseases with unmet need for a blood-based diagnostic